ABSTRACT: Warfarin remains a widely prescribed oral anticoagulant despite its narrow therapeutic index and its association with life-threatening bleeding events. This systematic review examined the ...
It’s reasonable, and perhaps preferable, to switch frail older patients with atrial fibrillation (AF) from a vitamin K antagonist like warfarin to a direct oral anticoagulant (DOAC) for stroke ...
BACKGROUND Diabetes mellitus (DM) is frequent among patients with atrial fibrillation (AF). The RE-LY trial permits a contemporary evaluation of comorbities, outcomes and the effectiveness of ...
Direct oral anticoagulants were associated with lower risks of ischemic stroke or systemic embolism and bleeding compared with warfarin. The study included patients with atrial fibrillation (AF) and ...
RIDGEFIELD, Conn., March 19, 2017 /PRNewswire/ -- Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial ...
The introduction of non–vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clinical trials may not translate ...
(HealthDay News) — For patients with atrial fibrillation, decline in renal function is significantly greater with warfarin versus dabigatran etexilate (DE), according to a study published in the ...
SILVER SPRING, MD (updated, corrected) — A massive study of Medicare patients at risk of stroke secondary to atrial fibrillation (AF) has found no signal of increased MI risk with dabigatran (Pradaxa, ...
Oral anticoagulation therapy is the primary tool in reducing stroke risk in patients with nonvalvular atrial fibrillation but is underused. Patients nonpersistent with therapy contribute to this ...
NEW YORK (Reuters) - For millions of heart patients, a pair of new blood thinners have been heralded as the first replacements in 60 years for warfarin, a pill whose hardships and risks have deterred ...
RIDGEFIELD, Conn., June 6, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the Pradaxa® (dabigatran etexilate mesylate) capsules prescribing information has been ...